(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 17.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Genmab A's revenue in 2024 is $2,777,013,177.On average, 5 Wall Street analysts forecast GMAB's revenue for 2024 to be $207,160,573,924, with the lowest GMAB revenue forecast at $201,498,659,281, and the highest GMAB revenue forecast at $210,807,429,223. On average, 6 Wall Street analysts forecast GMAB's revenue for 2025 to be $243,421,390,884, with the lowest GMAB revenue forecast at $230,381,970,180, and the highest GMAB revenue forecast at $253,817,583,884.
In 2026, GMAB is forecast to generate $299,620,567,938 in revenue, with the lowest revenue forecast at $276,730,716,007 and the highest revenue forecast at $328,811,547,737.